Advertisement

Phenomenology of Levodopa-Induced Dyskinesia

  • Panagiotis Zis
  • Kallol Ray Chaudhuri
  • Michael SamuelEmail author
Chapter

Abstract

Levodopa has been effective against the motor features of Parkinson’s disease for several decades. However, it is observed that long-term treatment with levodopa can be complicated by the development of various types of response fluctuations as well as dyskinesias. The latter, once established, tend to remain persistent although they can be reduced by some pharmacological and neurosurgical manipulations. These situations can lead to a significant source of disability, and their treatment options require significant expertise and costs. Therefore, efforts are made to minimize or prevent the appearance of long-term dyskinesia and fluctuations. In this chapter, we will consider the phenotypes of levodopa-induced dyskinesias.

Keywords

Levodopa-induced dyskinesia Phenomenology Levodopa Dyskinesia On-off 

Notes

Acknowledgment

The authors are grateful to Dr Davide Martino MD, PhD, King’s College Hospital, King’s Health Partners, London, for critical review of this chapter.

Supplementary material

Video 1.1

Peak dose (“ON”) leg and arm dyskinesia, while sitting, mainly choreic movement. On standing, some right arm additional dystonia (Video editing was kindly performed by Dr Veronica Bruno and Dr Tom Johnston) (MP4 1951 kb)

Video 1.2

Peak dose (“ON”) neck chorea, while walking. Some arm chorea (Video editing was kindly performed by Dr Veronica Bruno and Dr Tom Johnston) (MP4 5734 kb)

References

  1. 1.
    Barbeau A. L-dopa therapy in Parkinson’s disease: a critical review of nine years’ experience. Can Med Assoc J. 1969;101(13):59–68.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Schwab RS, England AC. Medical and surgical therapy of Parkinson’s disease. In: Fields WS, Charles C, editors. Pathogenesis and treatment of parkinsonism. Springfield: Thomas Publisher; 1958. p. 203.Google Scholar
  3. 3.
    Carlsson A, Lindqvist M, Magnusson T, Waldeck B. On the presence of 3-hydroxytyramine in brain. Science. 1958;127(3296):471.PubMedCrossRefGoogle Scholar
  4. 4.
    Carlsson A. The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev. 1959;11(2 Part 2):490–3.PubMedGoogle Scholar
  5. 5.
    Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr. 1960;38:1236–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Barbeau A. Preliminary observations on abnormal catecholamine metabolism in basal ganglia diseases. Neurology. 1960;10:446–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Barbeau A. Dopamine and basal ganglia diseases. Arch Neurol. 1961;4:97–102.PubMedCrossRefGoogle Scholar
  8. 8.
    Barbeau A, Murphy GF, Sourkes T. Excretion of dopamine in diseases of basal ganglia. Science. 1961;133(3465):1706–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Degkwitz R, Frowein R, Kulenkampff C, Mohs U. On the effects of L-dopa in man and their modification by reserpine, chlorpromazine, iproniazid and vitamin B6. Klin Wochenschr. 1960;38:120–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Shaw KM, Lees AJ, Stern GM. The impact of treatment with levodopa on Parkinson’s disease. Q J Med. 1980;49(195):283–93.PubMedGoogle Scholar
  11. 11.
    Friedman A. Levodopa-induced dyskinesia: clinical observations. J Neurol. 1985;232(1):29–31.PubMedCrossRefGoogle Scholar
  12. 12.
    Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RM, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Ostergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, van der Linden C, Oertel W. Selecting deep brain stimulation or infusion therapies in advanced Parkinson’s disease: an evidence-based review. J Neurol. 2013;260(11):2701–14.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83(980):384–8.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol. 1987;22(4):535–40.PubMedCrossRefGoogle Scholar
  15. 15.
    Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N. Intrajejunal levodopa infusion in advanced Parkinson’s disease: long-term effects on motor and non-motor symptoms and impact on patient’s and caregiver’s quality of life. Eur Rev Med Pharmacol Sci. 2012;16(1):79–89.PubMedGoogle Scholar
  16. 16.
    Müller T. Motor complications, levodopa metabolism and progression of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2011;7(7):847–55.PubMedCrossRefGoogle Scholar
  17. 17.
    Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Chérif AA. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002;59(3):408–13.PubMedCrossRefGoogle Scholar
  18. 18.
    van Laar T. Levodopa-induced response fluctuations in patients with Parkinson’s disease: strategies for management. CNS Drugs. 2003;17(7):475–89.PubMedCrossRefGoogle Scholar
  19. 19.
    Hametner E, Seppi K, Poewe W. The clinical spectrum of levodopa-induced motor complications. J Neurol. 2010;257 Suppl 2:S268–75.PubMedCrossRefGoogle Scholar
  20. 20.
    Leenders KL, Poewe WH, Palmer AJ, Brenton DP, Frackowiak RS. Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol. 1986;20(2):258–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Jost WH. Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci. 2010;289(1–2):69–73.PubMedCrossRefGoogle Scholar
  22. 22.
    Zesiewicz TA, Sullivan KL, Hauser RA. Levodopa-induced dyskinesia in Parkinson’s disease: epidemiology, etiology, and treatment. Curr Neurol Neurosci Rep. 2007;7(4):302–10.PubMedCrossRefGoogle Scholar
  23. 23.
    Jankovic JJ, Fahn S. Dystonic disorders. In: Jankovic JJ, Tolosa E, editors. Parkinson’s disease and movement disorders. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 331–57.Google Scholar
  24. 24.
    Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, Hallett M, Jankovic J, Jinnah HA, Klein C, Lang AE, Mink JW, Teller JK. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–73.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesia. Mov Disord. 2007;22(10):1379–89.PubMedCrossRefGoogle Scholar
  26. 26.
    Zehr EP, Sale DG. Ballistic movement: muscle activation and neuromuscular adaptation. Can J Appl Physiol. 1994;19(4):363–78.PubMedCrossRefGoogle Scholar
  27. 27.
    Jankovic J. Motor fluctuations and dyskinesia in Parkinson’s disease: clinical manifestations. Mov Disord. 2005;20 Suppl 11:S11–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med. 2000;342(20):1484–91.PubMedCrossRefGoogle Scholar
  29. 29.
    Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K, CALM-PD Investigators of the Parkinson Study Group. Impact of pramipexole on the onset of levodopa-related dyskinesia. Mov Disord. 2007;22(9):1317–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia (“I-D-I” and “D-I-D-”) in response to l-dopa therapy for Parkinson’s disease. Mayo Clin Proc. 1977;52(3):163–74.PubMedGoogle Scholar
  31. 31.
    Quinn NP. Classification of fluctuations in patients with Parkinson’s disease. Neurology. 1998;51(2 Suppl 2):S25–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Ilson J, Fahn S, Côté L. Painful dystonic spasms in Parkinson’s disease. Adv Neurol. 1984;40:395–8.PubMedGoogle Scholar
  33. 33.
    Melamed E. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson’s disease. Arch Neurol. 1979;36(5):308–10.PubMedCrossRefGoogle Scholar
  34. 34.
    Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson’s disease: clinical and pharmacological features. Ann Neurol. 1988;23(1):73–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Alegre M, López-Azcárate J, Alonso-Frech F, Rodríguez-Oroz MC, Valencia M, Guridi J, Artieda J, Obeso JA. Subthalamic activity during diphasic dyskinesia in Parkinson’s disease. Mov Disord. 2012;27(9):1178–81.PubMedCrossRefGoogle Scholar
  36. 36.
    Obeso JA, Grandas F, Vaamonde J, Luquin MR, Artieda J, Lera G, Rodriguez ME, Martinez-Lage JM. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology. 1989;39:11–9.PubMedGoogle Scholar
  37. 37.
    Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesia in Parkinson’s disease phenomenology and pathophysiology. Mov Disord. 1994;9:2–12.PubMedCrossRefGoogle Scholar
  38. 38.
    Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesia in Parkinson’s disease: clinical and pharmacological classification. Mov Disord. 1992;7:117–24.PubMedCrossRefGoogle Scholar
  39. 39.
    Jankovic J, Nour F. Respiratory dyskinesia in Parkinson’s disease. Neurology. 1986;36(2):303–4.PubMedCrossRefGoogle Scholar
  40. 40.
    Grötzsch H, Sztajzel R, Burkhard PR. Levodopa-induced ocular dyskinesia in Parkinson’s disease. Eur J Neurol. 2007;14(10):1124–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Rich MW, Radwany SM. Respiratory dyskinesia. An underrecognized phenomenon. Chest. 1994;105(6):1826–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Sacks OW, Kohl M, Schwartz W, Messeloff C. Side-effects of L-dopa in postencephalic parkinsonism. Lancet. 1970;1(7654):1006.PubMedCrossRefGoogle Scholar
  43. 43.
    Rice JE, Antic R, Thompson PD. Disordered respiration as a levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord. 2002;17(3):524–7.PubMedCrossRefGoogle Scholar
  44. 44.
    De Letter M, Santens P, De Bodt M, Van Maele G, Van Borsel J, Boon P. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson’s disease. Clin Neurol Neurosurg. 2007;109(6):495–500.PubMedCrossRefGoogle Scholar
  45. 45.
    De Keyser J, Vincken W. L-dopa-induced respiratory disturbance in Parkinson’s disease suppressed by tiapride. Neurology. 1985;35(2):235–7.PubMedCrossRefGoogle Scholar
  46. 46.
    LeWitt PA. Conjugate eye deviations as dyskinesia induced by levodopa in Parkinson’s disease. Mov Disord. 1998;13(4):731–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Linazasoro G, Van Blercom N, Lasa A, Indakoetxea B, Ruiz J. Levodopa-induced ocular dyskinesia in Parkinson’s disease. Mov Disord. 2002;17(1):186–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–508.PubMedCrossRefGoogle Scholar
  49. 49.
    Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;39(1):37–45.CrossRefGoogle Scholar
  50. 50.
    Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledó A, Wood A, Frewer P, Schwarz J. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET study. Mov Disord. 2006;21(3):343–53.PubMedCrossRefGoogle Scholar
  51. 51.
    Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA. 2000;284(15):1931–8.CrossRefGoogle Scholar
  52. 52.
    Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesia and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448–58.PubMedCrossRefGoogle Scholar
  53. 53.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O’Connell C, Ross T, Richard K, Watts A, Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61(7):1044–53.PubMedGoogle Scholar
  54. 54.
    López IC, Ruiz PJ, Del Pozo SV, Bernardos VS. Motor complications in Parkinson’s disease: ten year follow-up study. Mov Disord. 2010;25(16):2735–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord. 2007;22(16):2409–17.PubMedCrossRefGoogle Scholar
  56. 56.
    Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O. Clinical-pathological study of levodopa complications. Mov Disord. 2002;17(2):289–96.PubMedCrossRefGoogle Scholar
  57. 57.
    Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson’s disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20(2):190–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Manson A, Stirpe P, Schrag A. Levodopa-induced-dyskinesia clinical features, incidence, risk factors, management and impact on quality of life. J Parkinsons Dis. 2012;2(3):189–98.PubMedGoogle Scholar
  59. 59.
    Jankovic J. Parkinson’s disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001;114(3):227–34.Google Scholar
  60. 60.
    Mouradian MM, Heuser IJ, Baronti F, Fabbrini G, Juncos JL, Chase TN. Pathogenesis of dyskinesia in Parkinson’s disease. Ann Neurol. 1989;25(5):523–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Del Sorbo F, Albanese A. Levodopa-induced dyskinesia and their management. J Neurol. 2008;255 Suppl 4:32–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Van Gerpen JA, Kumar N, Bower JH, Weigand S, Ahlskog JE. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976–1990. Arch Neurol. 2006;63(2):205–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Hashim HZ, Norlinah MI, Nafisah WY, Tan HJ, Raymond AA, Tamil AM. Risk factors and predictors of levodopa-induced dyskinesia among multiethnic Malaysians with Parkinson’s disease. Int J Neurosci. 2014;124:187–91.PubMedCrossRefGoogle Scholar
  64. 64.
    Blanchet PJ, Allard P, Grégoire L, Tardif F, Bédard PJ. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can J Neurol Sci. 1996;23(3):189–93.PubMedGoogle Scholar
  65. 65.
    Quinn N, Marsden CD, Parkes JD. Complicated response fluctuations in Parkinson’s disease: response to intravenous infusion of levodopa. Lancet. 1982;2(8295):412–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Kurlan R, Rubin AJ, Miller C, Rivera-Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol. 1986;20(2):262–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Hauser RA, Hsu A, Kell S, Espay AJ, Sethi K, Stacy M, Ondo W, O’Connell M, Gupta S, IPX066 ADVANCE-PD investigators. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013;12(4):346–56.PubMedCrossRefGoogle Scholar
  68. 68.
    Ahlskog JE, Muenter MD, McManis PG, Bell GN, Bailey PA. Controlled-release Sinemet (CR-4): a double-blind crossover study in patients with fluctuating Parkinson’s disease. Mayo Clin Proc. 1988;63(9):876–86.PubMedCrossRefGoogle Scholar
  69. 69.
    Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S. Multicenter controlled study of Sinemet CR vs Sinemet (25/100) in advanced Parkinson’s disease. Neurology. 1989;39(11 Suppl 2):67–72.PubMedGoogle Scholar
  70. 70.
    Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology. 1999;53(5):1012–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Cedarbaum JM, Hoey M, McDowell FH. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson’s disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry. 1989;52(2):207–12.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Sage JI, Mark MH. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson’s disease: a double-blind, crossover study. Clin Neuropharmacol. 1988;11(2):174–9.PubMedCrossRefGoogle Scholar
  73. 73.
    Deleu D, Jacques M, Michotte Y, Ebinger G. Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations. Neurology. 1989;39(11 Suppl 2):88–92.PubMedGoogle Scholar
  74. 74.
    Stocchi F, Quinn NP, Barbato L, Patsalos PN, O’Connel MT, Ruggieri S, Marsden CD. Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. Clin Neuropharmacol. 1994;17(1):38–44.PubMedCrossRefGoogle Scholar
  75. 75.
    Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology. 1984;34(9):1131–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Schuh LA, Bennett Jr JP. Suppression of dyskinesia in advanced Parkinson’s disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesia but not for relief of parkinsonism in patients with advanced Parkinson’s disease. Neurology. 1993;43(8):1545–50.PubMedCrossRefGoogle Scholar
  77. 77.
    Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernäs H, Nyström C, Aquilonius SM. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26(3):156–63.PubMedCrossRefGoogle Scholar
  78. 78.
    Stocchi F, Bonamartini A, Vacca L, Ruggieri S. Motor fluctuations in levodopa treatment: clinical pharmacology. Eur Neurol. 1996;36 Suppl 1:38–42.PubMedCrossRefGoogle Scholar
  79. 79.
    Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient management. Expert Rev Neurother. 2009;9(6):859–67.PubMedCrossRefGoogle Scholar
  80. 80.
    Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, Aquilonius SM, Askmark H. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216–23.PubMedCrossRefGoogle Scholar
  81. 81.
    Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, Dal Fante M, Lopiano L, Pezzoli G. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord. 2007;22(8):1145–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008;31(3):151–66.PubMedCrossRefGoogle Scholar
  83. 83.
    Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism Relat Disord. 2013;19(3):339–45.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Rascol O. Extended-release carbidopa-levodopa in Parkinson’s disease. Lancet Neurol. 2013;12(4):325–6.PubMedCrossRefGoogle Scholar
  85. 85.
    Encarnacion EV, Hauser RA. Levodopa-induced dyskinesia in Parkinson’s disease: etiology, impact on quality of life, and treatments. Eur Neurol. 2008;60(2):57–66.PubMedCrossRefGoogle Scholar
  86. 86.
    Khlebtovsky A, Rigbi A, Melamed E, Ziv I, Steiner I, Gad A, Djaldetti R. Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesia. J Neural Transm. 2012;119(11):1367–71.PubMedCrossRefGoogle Scholar
  87. 87.
    Clarke CE, Worth P, Grosset D, Stewart D. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(10):728–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Panagiotis Zis
    • 1
    • 2
  • Kallol Ray Chaudhuri
    • 1
  • Michael Samuel
    • 1
    • 3
    Email author
  1. 1.Department of Neurology, National Parkinson Foundation International Centre of ExcellenceKing’s College Hospital, King’s Health PartnersLondonUK
  2. 2.Department of NeurologyEvangelismos General HospitalAthensGreece
  3. 3.East Kent Hospitals NHS Foundation TrustWilliam Harvey HospitalAshfordUK

Personalised recommendations